Skip to main content
. Author manuscript; available in PMC: 2013 Jan 1.
Published in final edited form as: J Thromb Haemost. 2012 Jan;10(1):107–115. doi: 10.1111/j.1538-7836.2011.04545.x

Figure 6. C1899/1903G disulfide mutation confers secretion advantage in vivo in a hemophilia A mouse model.

Figure 6

FVIII antigen (Panel A) and activity (Panel B) in the plasma of hemophilia A mice were measured by an ELISA and a COAMATIC chromogenic assay respectively, following transient expression of 226/N6-F309S and 226/N6-DM-F309S constructs by hydrodynamic tail vein injection as described under Methods. Data presented (○) represent multiple independent expression studies (N ≥ 5) with the mean indicated by a bar. *P < 0.05